Programmable RNA overcomes genetic medicine's liver limitation
The bull case for programmable mRNA platforms is their ability to deliver genetic instructions outside the liver to trigger systemic immune responses against metastatic cancers.
The argument
The guest argued that genetic medicine has been restricted to liver-targeted delivery for decades. By using programmable RNA to trick cancer cells into expressing their own destruction signals, therapies can trigger an abscopal effect that clears deep-tissue metastases throughout the body.
The thesis, stress-tested
✓ What validates it
- ✓Publication of expanded Phase 1/2 clinical trial data showing durable responses
- ✓Regulatory milestones such as FDA Fast Track or Orphan Drug designations
▸ Risks discussed
- ▸Early-stage clinical trial data from single patients may not scale to larger cohorts
- ▸High regulatory and clinical hurdles for novel mRNA delivery platforms
- ▸Potential for severe immune overactivation or toxicity
Hear it yourself
"genetic medicine, I would call it the holy grail for the last thirty years has been thinking about how do we administer intravenous, which means into the bloodstream, genetic medicines that can get to places throughout the body. We've been trapped in one organ for the past thirty years, and that's the liver."
00:00
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE